Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Lexeo Therapeutics Inc (LXEO)

Lexeo Therapeutics Inc (LXEO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Mon Dec 22, 6:30AM CST

NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc . (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases,...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum GlobeNewswire - Thu Dec 4, 7:00AM CST

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights GlobeNewswire - Wed Nov 5, 6:36AM CST

FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering GlobeNewswire - Mon Oct 20, 3:05PM CDT

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement GlobeNewswire - Thu Oct 16, 10:29PM CDT

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Thu Oct 16, 3:32PM CDT

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (the “Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics, Inc. (LXEO) Receives a Buy from Oppenheimer Tipranks - Thu Oct 9, 7:28AM CDT

Oppenheimer analyst Leland Gershell maintained a Buy rating on Lexeo Therapeutics, Inc. today and set a price target of $20.00. The company’s shares closed yesterday at $8.34.Elevate Your Investing Strategy:...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics Advances FDA Discussions for LX2006 Tipranks - Wed Oct 8, 5:36AM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Lexeo Therapeutics,...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy GlobeNewswire - Tue Oct 7, 5:00AM CDT

U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim...

LXEO : 10.56 (+1.15%)
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights GlobeNewswire - Thu Aug 14, 6:30AM CDT

Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia...

LXEO : 10.56 (+1.15%)

Barchart Exclusives

Super Micro Computer Stock Tumbles, But Investors are Piling into Its Call Options - Time to Buy SMCI? Barchart - 35 minutes ago
Super Micro Computer delivered disappointing quarterly results on Nov. 4. SMCI stock has tanked, as investors lost faith in this AI server company. However, large, unusual call options activity in SMCI may indicate that it could be time to buy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot